A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

Summary

For patients with non-resectable cholangiocarcinoma, gemcitabine with cisplatin is considered as the reference treatment in first line chemotherapy. However, the outcomes of these patients remain limited and therefore more effective drugs are warranted. The context of the disease and current data on sunitinib suggest that sunitinib may have activity in patients with advanced non resectable cholangiocarcinoma. Thereby, it is proposed to conduct an open label single arm trial aiming evidencing activity of sunitinib in such a patient population.

Timeline

Start

2011-09-01

Primary completion

2016-11-17

Completion

2016-11-17

Publications

• Gros L, Bouattour M, Dumont C, Dahan L, Malka D, Tijeras-Raballand A, De Gramont A, Ronot M, Dreyer C, Neuzillet C, Bourget P, Hadengue A, Roldan N, Garcia-Larnicol ML, Chibaudel B, Raymond E, Faivre S. Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial. Liver Int. 2025 Aug;45(8):e70196. doi: 10.1111/liv.70196.
• Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol. 2015 Apr 28;7(6):910-5. doi: 10.4254/wjh.v7.i6.910.

Drugs

Indications